ATE154362T1 - Verfahren zur herstellung von pai-2 - Google Patents

Verfahren zur herstellung von pai-2

Info

Publication number
ATE154362T1
ATE154362T1 AT90912919T AT90912919T ATE154362T1 AT E154362 T1 ATE154362 T1 AT E154362T1 AT 90912919 T AT90912919 T AT 90912919T AT 90912919 T AT90912919 T AT 90912919T AT E154362 T1 ATE154362 T1 AT E154362T1
Authority
AT
Austria
Prior art keywords
pct
pai
date
sec
compositions
Prior art date
Application number
AT90912919T
Other languages
English (en)
Inventor
Peter Lawrence Whitfeld
Michael Andrew Richardson
Clive Leighton Bunn
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ATE154362T1 publication Critical patent/ATE154362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT90912919T 1989-09-05 1990-09-04 Verfahren zur herstellung von pai-2 ATE154362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ617989 1989-09-05

Publications (1)

Publication Number Publication Date
ATE154362T1 true ATE154362T1 (de) 1997-06-15

Family

ID=3774166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90912919T ATE154362T1 (de) 1989-09-05 1990-09-04 Verfahren zur herstellung von pai-2

Country Status (11)

Country Link
US (1) US5298400A (de)
EP (1) EP0446315B1 (de)
JP (1) JPH04502108A (de)
KR (1) KR920701436A (de)
AT (1) ATE154362T1 (de)
CA (1) CA2041638C (de)
DE (1) DE69030920T2 (de)
DK (1) DK0446315T3 (de)
ES (1) ES2104610T3 (de)
NZ (1) NZ235182A (de)
WO (1) WO1991003556A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009124A1 (en) * 1989-12-20 1991-06-27 Biotech Australia Pty. Limited Variants of pai-2
GB9026737D0 (en) * 1990-12-08 1991-01-30 Delta Biotechnology Ltd Cancer treatment
AU2299592A (en) * 1991-07-02 1993-02-11 Children's Medical Center Corporation Treatment of periodontal disease with protease inhibitors
JPH09511220A (ja) * 1993-11-10 1997-11-11 ブリストル‐マイヤーズ スクイブ カンパニー バクテリアによって誘発される炎症性疾患の治療
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
JP2002526382A (ja) * 1998-04-01 2002-08-20 バイオテック・オーストラリア・ピーティーワイ・リミテッド 皮膚創傷の治療へのプロテアーゼ阻害剤の使用
AUPP508798A0 (en) 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
US7325244B2 (en) * 2001-09-20 2008-01-29 Keen Personal Media, Inc. Displaying a program guide responsive to electronic program guide data and program recording indicators
ES2367257T3 (es) 2002-04-25 2011-10-31 Shire Human Genetic Therapies, Inc. Tratamiento de deficit de alfa-galactosidasa a.
EP1587923B1 (de) 2003-01-22 2011-08-24 Duke University Verbesserte konstrukte zur expression lysosomaler polypeptide
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
GB2142078B (en) * 1983-06-23 1986-10-01 Wilmot Breeden Ltd Electrically-operated vehicle door latch
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
GB8517386D0 (en) * 1985-07-09 1985-08-14 Thompson J Karate protection mit
IL81879A (en) * 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
AU608752B2 (en) * 1986-03-13 1991-04-18 Australian National University, The Minactivin produced by recombinant dna technology
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
FR2611723B1 (fr) * 1987-02-27 1989-09-08 Transgene Sa Vecteur d'expression d'adn recombinant codant pour l'hirudine, cultures de cellules de mammiferes infectees ou transformees, procede de preparation de l'hirudine et proteine obtenue
JP2564536B2 (ja) * 1987-03-23 1996-12-18 株式会社 蛋白工学研究所 改良されたタンパク質分泌促進能を有するシグナルペプチドをコ−ドしているｄｎａ配列
DE3713272A1 (de) * 1987-04-18 1988-11-03 Behringwerke Ag Plasminogenaktivator-inhibitor, typ 2 (pai-2)
DE3722673A1 (de) * 1987-04-18 1989-01-19 Behringwerke Ag Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna

Also Published As

Publication number Publication date
ES2104610T3 (es) 1997-10-16
EP0446315A1 (de) 1991-09-18
WO1991003556A1 (en) 1991-03-21
DE69030920T2 (de) 1998-02-19
EP0446315B1 (de) 1997-06-11
AU629980B2 (en) 1992-10-15
DE69030920D1 (de) 1997-07-17
KR920701436A (ko) 1992-08-11
NZ235182A (en) 1993-01-27
US5298400A (en) 1994-03-29
CA2041638A1 (en) 1991-03-06
DK0446315T3 (da) 1998-01-05
CA2041638C (en) 2001-05-15
JPH04502108A (ja) 1992-04-16
EP0446315A4 (en) 1992-08-05
AU6283190A (en) 1991-04-08

Similar Documents

Publication Publication Date Title
Balian et al. Isolation of a collagen-binding fragment from fibronectin and cold-insoluble globulin.
Schmid et al. A short chain (pro) collagen from aged endochondral chondrocytes. Biochemical characterization.
TIMPL et al. Nature of the collagenous protein in a tumor basement membrane
Daamen et al. Comparison of five procedures for the purification of insoluble elastin
ATE80660T1 (de) Verfahren zur herstellung eines polypeptides.
ATE146219T1 (de) Polypeptid
ATE154362T1 (de) Verfahren zur herstellung von pai-2
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
KR960704934A (ko) 항혈전활성을 갖는 펩티드 및 이의 제조방법(Peptide having antithrombotic activity and process for producing the same)
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
YU218690A (sh) Postupak za pripremanje protein kompleksa u kojima deluje faktor viii:c
DE3852706D1 (de) Verfahren zur Herstellung eines physiologisch aktiven Peptids mit einem Cysteinrest.
KR910021477A (ko) 인체 단백질 c의 글리코실화 돌연변이체의 발현을 위한 벡터 및 화합물
DE69030937D1 (de) Mutanten von Interleukin-3
ATE253639T1 (de) Verfahren zur herstellung von peptiden
Elstow et al. Extraction, isolation and characterization of neutral salt soluble type V collagen from fetal calf skin
Brandt et al. Complete amino acid sequence of the N-terminal extension of calf skin type III procollagen
DE69310540D1 (de) Verhindern von spaltung von n-terminalen aminosäuren durch endogene aminopeptidasen während die expression von fremden genen in bakterien
Church Procollagen and collagen produced by normal bovine corneal stroma fibroblasts in cell culture.
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ATE250935T1 (de) Neuartige cytokine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee